Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04066023
Other study ID # CP-2019-001
Secondary ID
Status Completed
Phase Phase 2/Phase 3
First received
Last updated
Start date October 3, 2019
Est. completion date April 14, 2021

Study information

Verified date May 2022
Source Zosano Pharma Corporation
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a double-blind, placebo-controlled study. Subjects who meet the entry criteria will be randomized o receive one of three blinded treatments [C213 1.9 mg patch and placebo patch; C213 3.8 mg (1.9 mg x 2 patches), two placebo patches] on Day 1 and will have up to 48 weeks to confirm and treat a cluster headache. Subjects will self-administer the patches and respond to questions in the electronic diary (eDiary) until 1-hour post treatment administration.


Description:

This is a randomized, double-blinded, placebo-controlled study. Approximately 120 subjects who meet the entry criteria will be randomized 1:1:1 to receive one of three blinded treatments [C213 1.9 mg patch and placebo patch; C213 3.8 mg (1.9 mg x 2 patches), two placebo patches]. Qualified subjects will randomize to the double-blind treatment period at Day 1 and will have up to 48 weeks to confirm and treat a cluster headache. Using the eDiary to confirm they are experiencing a cluster headache, subjects will self-administer the patches and continue to respond to questions in the eDiary until 1-hour post treatment administration.


Recruitment information / eligibility

Status Completed
Enrollment 42
Est. completion date April 14, 2021
Est. primary completion date April 14, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: 1. Able to provide written informed consent 2. Women or men 18 to 65 years of age 3. Greater than 1-year history of episodic or chronic cluster headache with onset prior to 50 years of age. Diagnosis must comply with ICHD-3 (International Headache Society (IHS) diagnostic criteria). Diagnostic criteria must include a history of at least 5 attacks not attributed to any other disorder that include all of the following criteria: 1. Severe or very severe unilateral orbital, supraorbital and/or temporal pain lasting 45-180 minutes (average, when untreated) 2. Either or both of the following: 1. At least one of the following symptoms or signs, ipsilateral to the pain: 1. Conjunctival injection and/or lacrimation 2. Nasal congestion and/or rhinorrhea 3. Eyelid edema 4. Forehead and facial sweating 5. Miosis and or/ptosis 2. A sense of restlessness or agitation 3. Attacks have a frequency between one every other day and eight per day for more than half of the time when the disorder is active. 4. Not better accounted for by another International Classification of Headache Disorders (ICHD) diagnosis 4. Cluster history during the 12-month period prior to the screening visit must include: 1. At least 1 cluster period 2. Averaging 2-6 headaches per day 3. Lasting at least 7 days 5. Subject can distinguish cluster headaches from other headaches (i.e., migraine and tension-type headaches) 6. Women of child-bearing potential must not be pregnant, must agree to avoid pregnancy during the trial, and must use one of the following or be surgically sterilized: intrauterine device, or a hormonal contraceptive 7. Able to understand the operation of the electronic diary and able to apply the demo study drug patch correctly. Exclusion Criteria: 1. Contraindications to triptans 2. Use of any prohibited concomitant medications within 30 days of screening 3. History of hemiplegic migraine or migraine with brainstem aura 4. Participation in another investigational trial within 30 days or 5 half-lives of investigational product (whichever is longer). 5. Previous M207/C213 exposure in a clinical trial 6. Subject has other significant pain problems that might confound the study assessments in the opinion of the investigator 7. Diagnosis of any malignant disease (other than adequately treated or excised non-metastatic basal cell carcinoma or squamous cell carcinoma of the skin) within the 5 years prior to screening 8. History of unstable psychiatric illness requiring medication or hospitalization in the 12 months prior to study initiation 9. Subjects who have a known allergy or sensitivity to zolmitriptan or its derivatives or formulations 10. Subjects who have a known allergy or sensitivity to adhesions 11. Subjects who have skin lesions or tattoos covering the entire potential area(s) of C213 application 12. Woman who are pregnant, breast-feeding or plan a pregnancy during this study 13. Clinically significant liver disease [Alanine Aminotransferase (ALT) > 150 U/L; Aspartate Aminotransferase (AST) > 130 U/L or bilirubin > 2x ULN] 14. Clinically significant kidney disease (eGFR < 60 ml/min / 1.73 m² or to creatinine > 1.5 x ULN) 15. Subject has clinically significant ECG findings, defined by: 1. ischemic changes (defined as > 1mm of down-sloping ST segment depression in at least two contiguous leads) 2. Q-waves in at least two contiguous leads 3. clinically significant intra-ventricular conduction abnormalities (left bundle branch block or Wolf-Parkinson-White syndrome) 4. clinically significant arrhythmias (e.g., current atrial fibrillation) 16. History of coronary artery disease (CAD), coronary vasospasm (including Prinzmetal's angina), aortic aneurysm, peripheral vascular disease or other ischemic diseases (e.g., ischemic bowel syndrome or Raynaud's syndrome) 17. Three or more of the following CAD risk factors: 1. Current tobacco use 2. Hypertension (systolic BP > 140 or diastolic BP > 90) or receiving anti-hypertensive medication for treatment of hypertension 3. Hyperlipidemia - LDL > 159 mg/dL and/or HDL < 40 mg/dL (or on prescribed anti-cholesterol treatment) 4. Family history of premature coronary artery disease (CAD) (< 55 years of age in male first-degree relatives or < 65 years of age in female first degree relatives) 5. Diabetes mellitus 18. History of cerebral vascular accident (CVA), transient ischemic attacks (TIA), or seizures 19. History of concurrent illness that requires hospitalization within 30 days prior to study initiation 20. Any other household member currently participating in a C213 study or relative of site staff member 21. Any reason to believe that compliance with the study requirements and completion of evaluations required for this study will not be possible 22. Any language barrier that, in the opinion of the Investigator, would preclude communication and compliance with the study requirements 23. History or current abuse of or dependence on alcohol or drugs that would interfere with the results or adherence to study requirements 24. Any positive drug screens for phencyclidine (PCP), 3,4-methylenedioxy-methamphetamine (MDMA) (ecstasy), cocaine, and/or meth/amphetamine(s) 25. Current or planned use of hallucinogens (e.g. psilocybin) during the trial 26. Any clinically relevant abnormal findings in the physical exam, vital signs or laboratory tests that, in the opinion of the Investigator, may put the subject at risk

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
C213 Microneedle System
The C213 System is a proprietary disposable patch and a reusable applicator. The zolmitriptan-coated titanium microneedle array (3 cm^2 array) is attached to a 5 cm^2 adhesive patch.
Placebo
The C213 System is a proprietary disposable patch and a reusable applicator. The placebo patch is a single use, 3 cm^2 Placebo (intracutaneous microneedle) system that contains no active ingredients.

Locations

Country Name City State
United States Dent Neuro Institute, Buffalo Amherst New York
United States Atlanta Headache Specialists Atlanta Georgia
United States University of Texas Southwestern Medical Center- Neurology Clinic Dallas Texas
United States Nevada Headache Institute Las Vegas Nevada
United States Dartmouth Hitchcock Medical Center Lebanon New Hampshire
United States Keck Medicine of USC Los Angeles California
United States Medstar Georgetown University Hospital at McLean McLean Virginia
United States Stanford University Palo Alto California
United States Jefferson Headache Center Philadelphia Pennsylvania
United States California Medical Clinic for Headache Santa Monica California
United States KI Health Partners LLC DBA New England Institute for Clinical Research Stamford Connecticut
United States New England Regional Headache Center, Inc. Worcester Massachusetts

Sponsors (1)

Lead Sponsor Collaborator
Zosano Pharma Corporation

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Subjects Who Achieve Pain Relief Pain relief is defined by a decrease in pain from severe to mild or none without the use of acute rescue medication. 15 minutes
Primary Percentage of Subjects Who Achieve Sustained Pain Relief Sustained pain relief requires a pain rating of mild or none at each timepoint from 15 minutes to 60 minutes without the use of acute rescue medication. 15 minutes to 60 minutes
Secondary Percentage of Subjects That Achieve Pain Relief Pain relief is defined by a decrease in pain from severe to mild or none without the use of acute rescue medication. 5 minutes
Secondary Percentage of Subjects That Achieve Sustained Pain Relief Sustained pain relief requires a pain rating of mild or none at each timepoint within the time frame without the use of acute rescue medication. 5 minutes to 60 minutes
Secondary Percentage of Subjects That Achieve Pain Freedom Pain freedom is defined by a decrease in pain from severe to none without the use of acute rescue medication. 10 minutes
Secondary Percentage of Subjects That Achieve Sustained Pain Freedom Sustained pain freedom requires a pain rating of none at each timepoint within the time frame without the use of acute rescue medication. 15 to 60 minutes
Secondary Percentage of Subjects Able to Perform Their Usual Daily Activities as Assessed by the Subject Whether or not subjects were able to perform their usual daily activities was assessed by subject responses (Yes or No) in the electronic diary (eDiary) to the question, "Do you feel able to perform your usual daily activities?" If a subject responded "Yes" but had used a rescue medication, the subject was considered as not being able to perform the usual daily activities. within 20 minutes
Secondary Percentage of Subjects That Achieve Pain Relief Pain relief is defined by a decrease in pain from severe to mild or none without the use of acute rescue medication 10 minutes
Secondary Percentage of Subjects That Achieve Pain Relief Pain relief is defined by a decrease in pain from severe to mild or none without the use of acute rescue medication. 20 minutes
Secondary Percentage of Subjects That Achieve Sustained Pain Relief Sustained pain relief requires a pain rating of mild or none at each timepoint within the time frame without the use of acute rescue medication. 10 minutes to 60 minutes
Secondary Percentage of Subjects That Achieve Pain Freedom Pain freedom is defined by a decrease in pain from severe to none without the use of acute rescue medication. 20 minutes
See also
  Status Clinical Trial Phase
Recruiting NCT05264714 - Cluster Headache Treatment With Rimegepant Phase 2
Completed NCT01677026 - Data Collection on the ATI Neurostimulation System: SPG Stimulation for Cluster Headache
Terminated NCT00203190 - A Double-Blind, Placebo-Controlled Study Examining the Use of Topiramate in the Treatment of Cluster Headache Phase 4
Terminated NCT04570475 - High Dose Vitamin D Plus Multivitamin in the Prevention of Cluster Headache Phase 3
Withdrawn NCT04353505 - Intra-arterial Sphenopalatine Ganglion Block for Patients With Refractory Headache Phase 1
Completed NCT02019017 - Botox Injection in Treatment of Cluster Headache Phase 1/Phase 2
Completed NCT05153876 - An Open Internet-based Survey and Natural Language Processing Project Analysing Written Monologues by Headache Patients
Recruiting NCT05324748 - Repeated GON Injections in CCH Phase 3
Completed NCT02782533 - DBS of the Third Ventricle for Cluster Headache and Obesity N/A
Completed NCT04179266 - Effect of Ketamine Intranasal Spray in Treatment of Chronic Cluster Headache Phase 1/Phase 2
Recruiting NCT04406259 - Atrioventricular Block and Cluster Headache (SEVA) Phase 4
Recruiting NCT06206772 - Resting State Functional Connectivity in Cluster Headache
Recruiting NCT03944876 - Botulinum Toxin Type A Blockade of the Sphenopalatine Ganglion in Treatment-refractory Chronic Cluster Headache Phase 3
Not yet recruiting NCT05857098 - Detection of Local Field Potentials in the Ventral Tegmental Area of the Midbrain in Chronic Cluster Headache Patients
Recruiting NCT02910323 - The Will Erwin Headache Research Center - Cluster Headache Study
Terminated NCT00458770 - Study of Hypothalamic Metabolism in Spontaneous Cluster Headache Attacks N/A
Completed NCT00662935 - Evaluation of Efficacity and Safety of Deep Brain Stimulation (DBS) in Chronic and Treatment-Resistant Cluster Headache(CH) N/A
Active, not recruiting NCT03511846 - Pain Biomarker Study Phase 1
Completed NCT00184587 - Prophylactic Treatment of Episodic Cluster Headache Phase 2
Not yet recruiting NCT06277063 - nVNS for the Prevention and Treatment of Primary Headache N/A